Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is 2.41%. On last trading day company shares ended up $9.34. Analysts mean target price for the company is $19.20. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average is -7.30%.
Synthetic Biologics Inc (NYSEMKT:SYN) is teaming up with gut microbiome specialists Enterome Bioscience to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora of human patients. The two firms say they plan to begin their 100-patient study next month and hope to have it completed in the second half of 2014.Synthetic Biologics Inc (NYSEMKT:SYN) shares fell -9.15% in last trading session and ended the day on $1.49. SYN its return on assets is -122.50%. Synthetic Biologics Inc (NYSEMKT:SYN) quarterly performance is -46.40%.
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, announced it has secured a loan facility of up to $35 million with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”).Relypsa Inc (NASDAQ:RLYP) shares moved down 7.36% in last trading session and was closed at $22.91, while trading in range of $22.23-$24.97. Relypsa Inc (NASDAQ:RLYP) year to date performance is -8.36%.
OHR Pharmaceutical Inc (NASDAQ:OHRP), a research and development company with a primary focus in ophthalmology, announced the closing of its previously announced acquisition of the assets of SKS Ocular LLC. In connection with this transaction, three of the cofounders of SKS Ocular are being appointed to senior management and advisory roles at Ohr. Jason Slakter, MD has been appointed Chief Medical Officer and is expected to join the Board of Directors. OHR Pharmaceutical Inc (NASDAQ:OHRP) ended the last trading day at $8.60. Company weekly volatility is calculated as 6.59% and price to cash ratio as 50.78. OHR Pharmaceutical Inc (NASDAQ:OHRP) showed a negative weekly performance of -1.26%.
Synergetics Usa (NASDAQ:SURG) issued its quarterly earnings data on Monday. The company reported $0.04 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.04. Synergetics USA Inc (NASDAQ:SURG) net profit margin is 5.10% and weekly performance is -2.48%. On last trading day company shares ended up $3.15. Analysts mean target price for the company is $6.00. Synergetics USA Inc (NASDAQ:SURG) distance from 50-day simple moving average is -5.75%.